CXCL9、CXCL10、CXCL11/CXCR3轴在调控肿瘤及治疗方面的作用  

The role of CXCL9,CXCL10,CXCL11/CXCR3 axes in tumor regulation and therapy

作　　者：赵永馨 周陈静雯 刘畅[1] 卫彬(综述)[1] 高勇(审校)[1] ZHAO Yongxin;ZHOU Chenjingwen;LIU Chang;WEI Bin;GAO Yong(Department of Oncology,the First Affiliated Hospital of Huaian,Nanjing Medical University,Nanjing,Jiangsu 223300,China)

机构地区：[1]南京医科大学附属淮安第一医院肿瘤内科,江苏南京223300

出　　处：《检验医学与临床》2025年第8期1148-1152,共5页Laboratory Medicine and Clinic

基　　金：国家自然科学基金青年科学基金项目(82103318);江苏省自然科学基金面上项目(BK20211112)。

摘　　要：趋化因子是一种可以由肿瘤细胞和基质细胞产生的小分子分泌蛋白,分为CXC、CC、CX3C及C 4大类,研究较多的亚型为CXC。其中CXC趋化因子配体(CXCL)9、10、11通过与其同源CXC趋化因子受体3(CXCR3)相互作用在免疫系统中发挥重要作用,与恶性肿瘤密切的发生、发展过程相关。该文对CXCL9、CXCL10、CXCL11/CXCR3轴的研究进展进行综述,包括三者直接调控肿瘤细胞的增殖与转移、对血管内皮细胞的间接调控、在肿瘤微环境中介导细胞的定向移动及与免疫治疗之间的关系。此外,还讨论了调控趋化因子与其他疗法相结合治疗癌症的潜力。Chemokines are small molecule secreted proteins produced by tumor cells and stromal cells,which can be divided into CXC,CC,CX3C and C,and the CXC is the most studied subtype.CXC chemokine ligands(CXCL)9,10 and 11 play an important role in the immune system by interacting with their homologous CXC chemokine receptor 3(CXCR3),and are closely related to the occurrence and development of malignant tumors.In this review,the research progress of CXCL9,CXCL10,CXCL11/CXCR3 axis was reviewed,including their direct regulation of tumor cell proliferation and metastasis,indirect regulation of vascular endothelial cells,mediating cell targeted movement in tumor microenvironment,and its relationship with immunotherapy.In addition,the potential of regulating chemokines in combination with other therapies to treat cancer is discussed.

关 键 词：CXC趋化因子配体10 CXC趋化因子配体9 CXC趋化因子配体11 CXC趋化因子受体3 肿瘤微环境 治疗 

分 类 号：R730.53[医药卫生—肿瘤] R730.23[医药卫生—临床医学]